1 | 李樱媚, 陈历排, 陈 孝. 人原代卵巢肿瘤细胞体外培养的药敏研究及其在临床的应用[J]. 今日药学, 2016, 26(5): 291-294. |
2 | ROKITA J L, RATHI K S, CARDENAS M F, et al. Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design[J]. Cell Rep, 2019, 29(6): 1675-1689. |
3 | 周君涵, 邹双微, 朱雪琼. PDX模型在妇科恶性肿瘤靶向治疗方面的应用[J]. 现代妇产科进展, 2020, 29(4): 308-312. |
4 | ZHAN M, YANG R M, WANG H, et al. Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients[J]. Cancer Commun (Lond), 2018, 38(1): 48. |
5 | ARMSTRONG D K, ALVAREZ R D, BAKKUM-GAMEZ J N, et al. NCCN guidelines insights: ovarian cancer, version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(8): 896-909. |
6 | 陈漪雯, 刘妮龙, 姜昊声, 等. OncoVee MiniPDXTM模型指导驱动基因阴性的晚期非小细胞肺癌患者化疗的疗效分析[J]. 实用癌症杂志, 2019, 34(8): 1325-1327. |
7 | 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准: RECIST[J]. 循证医学, 2004, 4(2): 85-90. |
8 | BAUER A G, JEFFERSON M, NAHHAS G J, et al. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system[J]. Cancer Med, 2020, 9(23): 8765-8771. |
9 | 罗素娟, 高 燕, 唐 洁. 肿瘤细胞减灭术在复发性卵巢癌中的应用进展[J]. 现代妇产科进展, 2019, 28(7): 547-550. |
10 | MCGRANAHAN N, SWANTON C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628. |
11 | SU D, ZHANG D D, JIN J Y, et al. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma[J]. Nat Commun, 2019, 10(1): 5076. |
12 | CHOI S Y, LIN D, GOUT P W, et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer[J]. Adv Drug Deliv Rev, 2014, 79/80: 222-237. |
13 | XU Y H, ZHANG F F, PAN X Q, et al. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance[J]. Cancer Commun (Lond), 2018, 38(1): 19. |
14 | ZHAO P, CHEN H, WEN D Y, et al. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma[J]. Cancer Commun (Lond), 2018, 38(1): 54. |
15 | LAI Y X, WEI X R, LIN S H, et al. Current status and perspectives of patient-derived xenograft models in cancer research[J].J Hematol Oncol,2017,10(1):106. |
16 | 张喜梅, 马国芳, 陈玉芬. 卵巢肿瘤细胞体外药物敏感试验临床应用价值[J]. 中国生化药物杂志, 2015, 35(4): 84-87. |
17 | BIZZARO F, FALCETTA F, D'AGOSTINI E, et al. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab[J]. Int J Cancer, 2018, 143(9): 2187-2199. |
18 | 关晓青, 孟凡良, 龚时鹏. 多柔比星脂质体在复发性卵巢癌中的应用进展[J]. 妇产与遗传(电子版), 2020, 10(1): 50-54. |
19 | ISHIKURA N, YOROZU K, KURASAWA M, et al. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model[J]. Oncol Rep, 2019, 42(3):1057-1065. |
20 | 由婷婷, 谷俊杰, 白春梅, 等. 白蛋白结合型紫杉醇治疗卵巢癌的Meta分析[J]. 中国新药杂志, 2020, 29(17): 2027-2033. |
21 | CAO X, HOU J Y, AN Q L, et al. Towards the overcoming of anticancer drug resistance mediated by p53 mutations[J]. Drug Resist Updat, 2020, 49: 100671. |
22 | 赵长燕, 贺红梅, 邵长好, 等. IMP3、P16蛋白、HE4、P53蛋白在卵巢浆液性肿瘤中表达及其临床意义[J]. 国际检验医学杂志, 2019, 40(6): 678-682. |
23 | 廖寿雁, 郭苑莉. 卵巢浆液性肿瘤中WT-1异常活化对ki-67和P53蛋白表达的调控作用[J]. 解剖学研究, 2017, 39(2): 119-122. |
24 | 张瑞涛,史惠蓉,刘哲颖,等.卵巢上皮性癌组织中miR-338-3p的表达[J].郑州大学学报(医学版),2019,54(5):780-783. |
25 | HARDY L R, SALVI A, BURDETTE J E. UnPAXing the divergent roles of PAX2 and PAX8 in high-grade serous ovarian cancer[J]. Cancers (Basel), 2018, 10(8): E262. |
26 | 苟思琪, 方 媛, 张 前, 等. CK7、CK20联合肠道源性标志物检测在肺肠型腺癌和转移性结直肠腺癌鉴别诊断中的价值[J]. 临床与实验病理学杂志, 2020, 36(3): 275-280. |